Giancarlo Maria Liumbruno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Giancarlo Maria Liumbruno has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Giuliano Grazzini
Italian National Blood Centre, National Institute of Health, Rome, Italy
13 shared publicationsSimonetta Pupella
Italian National Blood Centre, National Institute of Health, Rome, Italy
8 shared publicationsAngela Lattanzio
Service of Immunohaematology and Transfusion Medicine, Hospital of Carbonara, Bari
7 shared publicationsDaniela Rafanelli
Immunohaematology and Transfusion Medicine Unit, AUSL 3 Pistoia, Italy
7 shared publicationsFrancesco Bennardello
Service of Immunohaematology and Transfusion Medicine, “Civile-Maria Paternò Arezzo” Hospital, Ragusa
7 shared publicationsPierluigi Piccoli
Service of Immunohaematology and Transfusion Medicine, Hospital of Verona, Verona
7 shared publications
Latest Publications
- 1 February 2022
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 29 (1) , 101-102
Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
- 1 February 2022
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 29 (1) , 101-102
Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
- 1 December 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (6) , 103216
Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
- 1 December 2021
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (6) , 103216
Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
- Open Access
The Three Pillars of COVID-19 Convalescent Plasma Therapy
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread rapidly around the world in the last year causing the coronavirus disease 2019 (COVID-19), which still is a severe threat for public health. The therapeutic management of COVID-19 is challenging as, up until now, no specific and efficient pharmacological therapy has been validated. Translating the experience from previous viral epidemics, passive immunotherapy by means of plasma from individuals recovered from COVID-19 has been intensively investigated since the beginning of the pandemic. In this narrative review, we critically analyze the three factors, named “pillars”, that play a key role in determining the clinical effectiveness of this biologic therapy: the convalescent plasma, the disease (COVID-19), and the patients.
Open AccessThe Three Pillars of COVID-19 Convalescent Plasma Therapy
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread rapidly around the world in the last year causing the coronavirus disease 2019 (COVID-19), which still is a severe threat for public health. The therapeutic management of COVID-19 is challenging as, up until now, no specific and efficient pharmacological therapy has been validated. Translating the experience from previous viral epidemics, passive immunotherapy by means of plasma from individuals recovered from COVID-19 has been intensively investigated since the beginning of the pandemic. In this narrative review, we critically analyze the three factors, named “pillars”, that play a key role in determining the clinical effectiveness of this biologic therapy: the convalescent plasma, the disease (COVID-19), and the patients.
- Open Access
- 1 February 2021
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. ume 15, 31-38
Convalescent Plasma for the Treatment of Severe COVID-19
The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients’ clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.
- 1 February 2021
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. ume 15, 31-38
Open AccessConvalescent Plasma for the Treatment of Severe COVID-19
The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients’ clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.
- 1 January 2015
- Vol. 13 (1) , 159-160
Fibrinogen concentrate as haemostatic therapy in acquired bleeding disorders: not only a question of dosing strategies and thresholds
- 1 January 2015
- Vol. 13 (1) , 159-160
Fibrinogen concentrate as haemostatic therapy in acquired bleeding disorders: not only a question of dosing strategies and thresholds
- 1 January 2015
- Vol. 14 (2) , 1-6
Convalescent plasma: new evidence for an old therapeutic tool?
Passive immunisation for the prevention and treatment of human infectious diseases can be traced back to the 20(th) century. The recent Ebola virus outbreak in West Africa has turned the spotlight onto the possible use of convalescent whole blood and convalescent plasma in the treatment of infectious diseases because they are the only therapeutic strategy available in some cases, given the unavailability of vaccines, drugs or other specific treatments. Convalescent blood products could be a valid option in the treatment/prophylaxis of several infectious diseases both in association with other drugs/preventive measures and as the only therapy when a specific treatment is not available. However, there are still some issues to consider in determining the advisability of implementing a large-scale convalescent plasma transfusion programme.
- 1 January 2015
- Vol. 14 (2) , 1-6
Convalescent plasma: new evidence for an old therapeutic tool?
Passive immunisation for the prevention and treatment of human infectious diseases can be traced back to the 20(th) century. The recent Ebola virus outbreak in West Africa has turned the spotlight onto the possible use of convalescent whole blood and convalescent plasma in the treatment of infectious diseases because they are the only therapeutic strategy available in some cases, given the unavailability of vaccines, drugs or other specific treatments. Convalescent blood products could be a valid option in the treatment/prophylaxis of several infectious diseases both in association with other drugs/preventive measures and as the only therapy when a specific treatment is not available. However, there are still some issues to consider in determining the advisability of implementing a large-scale convalescent plasma transfusion programme.
- 1 January 2015
- Vol. 14 (2) , 95-100
Zika virus and the never-ending story of emerging pathogens and transfusion medicine
In the last few years, the transfusion medicine community has been paying special attention to emerging vector-borne diseases transmitted by arboviruses. Zika virus is the latest of these pathogens and is responsible for major outbreaks in Africa, Asia and, more recently, in previously infection-naïve territories of the Pacific area. Many issues regarding this emerging pathogen remain unclear and require further investigation. National health authorities have adopted different prevention strategies. The aim of this review article is to discuss the currently available, though limited, information and the potential impact of this virus on transfusion medicine
- 1 January 2015
- Vol. 14 (2) , 95-100
Zika virus and the never-ending story of emerging pathogens and transfusion medicine
In the last few years, the transfusion medicine community has been paying special attention to emerging vector-borne diseases transmitted by arboviruses. Zika virus is the latest of these pathogens and is responsible for major outbreaks in Africa, Asia and, more recently, in previously infection-naïve territories of the Pacific area. Many issues regarding this emerging pathogen remain unclear and require further investigation. National health authorities have adopted different prevention strategies. The aim of this review article is to discuss the currently available, though limited, information and the potential impact of this virus on transfusion medicine
- 1 July 2014
- Vol. 12 (3) , 287-289
Intravenous iron and safety: is the end of the debate on the horizon?
- 1 July 2014
- Vol. 12 (3) , 287-289
Intravenous iron and safety: is the end of the debate on the horizon?
- Open Access
- 21 May 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 39 (1) , 118-128
Solvent/detergent plasma: pharmaceutical characteristics and clinical experience
The solvent/detergent treatment is an established virus inactivation technology that has been industrially applied for manufacturing plasma derived medicinal products for almost 30 years. Solvent/detergent plasma is a pharmaceutical product with standardised content of clotting factors, devoid of antibodies implicated in transfusion-related acute lung injury pathogenesis, and with a very high level of decontamination from transfusion-transmissible infectious agents. Many clinical studies have confirmed its safety and efficacy in the setting of congenital as well as acquired bleeding disorders. This narrative review will focus on the pharmaceutical characteristics of solvent/detergent plasma and the clinical experience with this blood product.
- 21 May 2014
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 39 (1) , 118-128
Open AccessSolvent/detergent plasma: pharmaceutical characteristics and clinical experience
The solvent/detergent treatment is an established virus inactivation technology that has been industrially applied for manufacturing plasma derived medicinal products for almost 30 years. Solvent/detergent plasma is a pharmaceutical product with standardised content of clotting factors, devoid of antibodies implicated in transfusion-related acute lung injury pathogenesis, and with a very high level of decontamination from transfusion-transmissible infectious agents. Many clinical studies have confirmed its safety and efficacy in the setting of congenital as well as acquired bleeding disorders. This narrative review will focus on the pharmaceutical characteristics of solvent/detergent plasma and the clinical experience with this blood product.